Filing Flows › Sarepta Therapeutics (SRPT) › Q2 2026
Sarepta Therapeutics (SRPT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Sarepta Therapeutics (SRPT) reported revenue of $401M for the second quarter 2026 (Q2 2026), -34% from a year earlier and -45% from the quarter before. Operating margin was 3.3%, net loss $4.9M (1.2% of revenue).
Sarepta Therapeutics, Q2 2026: revenue $401M (-34% year over year), operating margin 3.3%, net loss $4.9M, operating cash flow $197M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $401M | -45% | -34% |
| Operating profit | $13.3M | -96% | -89% |
| Net earnings | −$4.9M | -101% | -102% |
| Operating cash flow | $197M | — | -25% |
| Free cash flow | $197M | — | -14% |
What changed
Revenue was $401.3M in Q2 2026, down 34% year over year and down 45% from the previous quarter. Pmo Products was the largest line at 57% of revenue. Elevidys lost $183.7M year over year (down 65%), 88% of the total change.
Operating profit was $13.3M, a 3.3% margin (down 15.6 points year over year). The quarter ended with a net loss of $4.9M, after a profit of $331.0M the previous quarter. Net interest and other expense of $15.0M was the main reason.
Operating cash flow was $197.1M (down 25% year over year). Non-cash charges added back $10.4M of depreciation and amortization and $24.5M of share-based compensation. Working capital and other items added $167.1M. Capital expenditures of $555K left free cash flow of $196.5M.
Questions
What was Sarepta Therapeutics' revenue in the second quarter 2026?
Sarepta Therapeutics (SRPT) reported revenue of $401M for the second quarter 2026 (Q2 2026), -34% from a year earlier and -45% from the quarter before.
Was Sarepta Therapeutics profitable in the second quarter 2026?
Operating profit was $13.3M (3.3% of revenue) and net loss $4.9M.